Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.
News|Videos|March 15, 2024
Safety and Efficacy of Axatilimab in Patients With Chronic Graft-Versus-Host Disease (AGAVE-201)
Author(s)Zachariah DeFilipp, MD
Zachariah DeFilipp, MD, presents data from AGAVE-201, a phase 2, open-label, randomized, multicenter study evaluating axatilimab at 3 dose levels in patients with recurrent/refractory chronic graft-versus-host disease (GVHD).
Advertisement
Advertisement
Related to this article
A collaborative research initiative will unite two comprehensive inflammatory breast cancer clinics.
Ris-rez improved PFS vs chemotherapy in the ARTEMIS-011 trial for relapsed/refractory osteosarcoma.
Sanja Dacic, MD, PhD, outlines advances that are reshaping molecular profiling in advanced non–small cell lung cancer and how to navigate these changes.
Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.
Phase 3 BOND-003 cohort C findings showed a 75.5% CR rate and durable bladder preservation in high-risk, BCG-unresponsive NMIBC.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Laurence J. DiNardo, MD, FACS, discusses ctDNA testing in head and neck cancers, advancements in targeted therapies, and multidisciplinary collaboration.
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
3
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
4
Cretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC
5